Molecular markers of glioblastoma such as MGMT methylation were seen in two of the six patients evaluated (33.3%); epidermal growth factor receptor (EGFR) expression was seen in 14 patients; expression of tumor markers for drug resistance such as multidrug resistance protein-1 (MDR-1) and multiple resistance protein (MRP) was seen in 28 patients; and expression of Nestin, Glial fibrillary acidic protein (GFAP), Ki-67, and immunological markers such as CD133, CD140, and TUJ-1 were evaluated in two patients (Table 2). The gene discussed is PROM1; the disease is neoplasm.